We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
Cumberland Pharmaceuticals declares $1.50 dividend - MSN
Cumberland Pharmaceuticals declares $1.50 dividend MSN
Cumberland Pharma Board of Directors Has Authorized and Declared a Special Cash Div of $1.50 a Shr >CPIX - Moomoo
Cumberland Pharma Board of Directors Has Authorized and Declared a Special Cash Div of $1.50 a Shr >CPIX Moomoo
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - Zacks Investment Research
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? Zacks Investment Research
BRIEF-Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share - Dailyhunt
BRIEF-Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share Dailyhunt
Cumberland Pharmaceuticals 8-K Filing July 2026: Key Company Details, Stock Info, and Address on NASDAQ CPIX - Minichart
Cumberland Pharmaceuticals 8-K Filing July 2026: Key Company Details, Stock Info, and Address on NASDAQ CPIX Minichart
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | — | — | — | — | — | Scheduled |
| FY2025 Q1 | 2025. 03. 31. | Time TBD | — | $0.08 | — | — | $11.71M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.32 | — | — | $27.43M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.21 | — | — | $18.35M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2019. 12. 03. | B. Riley Securities | — | Maintain | — → Buy | — | B. Riley Securities: Buy |
| 2019. 11. 19. | B. Riley Securities | — | Maintain | — → Buy | — | B. Riley Securities: Buy |
| 2018. 08. 17. | B. Riley Securities | — | Maintain | Buy → Buy | — | B. Riley Securities: Buy |
| 2018. 04. 17. | B. Riley Securities | — | Initiate coverage | — → Buy | — | B. Riley Securities: Buy |
| 2013. 04. 10. | UBS | — | Maintain | — → Neutral | — | UBS: Neutral |
| 2012. 11. 13. | UBS | — | Maintain | — → Neutral | — | UBS: Neutral |
As of FY2025Q3 · Source: SEC/DART + price data
No holdings data to show.